- Details
- Description
Packaging Size:
50 mg × 10 tablets × 6 blisters (60 tablets)
Strength:
50 mg per tablet
Composition:
Gecacitinib hydrochloride
Treatment:
Myelofibrosis (MF), including primary myelofibrosis and myelofibrosis following polycythemia vera or essential thrombocythemia.
Form:
Film-coated tablets
Brand:
Zepuping® (泽普平®)
Quantity Unit:
Box
Manufacturer:
Suzhou Zelgen Biopharmaceuticals Co., Ltd., Kunshan, Jiangsu, China.
Zepuping (Gecacitinib) is an oral targeted therapy that belongs to the Janus kinase (JAK) inhibitor class. It works by blocking specific JAK signaling pathways that play an important role in the immune response and the development of inflammation. By reducing these signals, gecacitinib may help decrease inflammatory activity and related symptoms. It is being developed for the treatment of certain inflammatory and autoimmune diseases and may be administered as a convenient oral treatment, depending on the indication and prescribed dosage.
